Journal Mobile Options
Table of Contents
Vol. 24, No. 2, 2006
Issue release date: February 2006
Blood Purif 2006;24:236–246

uPAR (CD87) as a Biocompatibility Marker of Dialysis Membrane

Sohka T. · Ohno T. · Ichinose M. · Okonogi H. · Kawaguchi Y. · Hosoya T. · Nakamura K. · Kataoka E. · Suzuki M. · Koremoto M. · Sumita M. · Shirai T. · Kasai K.
aSecond Department, Central Technology Laboratory, Asahi Kasei Corporation and bLaboratory for Biology, Asahi Kasei Pharma, Fuji; cDivision of Nephrology and Hypertension, Jikei University, School of Medicine, Tokyo; dFuji Daiichi Clinic, Fuji; eDialysis Products Division, Asahi Kasei Medical, Tokyo; fFuji City General Hospital, Fuji, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background/Aims: Hemodialysis (HD) therapy may lead to functional changes in patient leukocytes. For example, the upregulation of inflammatory cytokines, such as IL-1β and TNFα, has been well characterized. However, these findings do not explain the entire response of leukocytes in HD. In this study, we carried out a comprehensive gene expression analysis in leukocytes treated with various dialysis membranes using DNA microarrays. The identified gene has the potential to be a new marker for testing dialysis membrane biocompatibility. Methods: Gene expression profiles were compared between a group of leukocytes treated with various dialysis membranes and an untreated group by using DNA microarray analysis. Expression was confirmed by quantitative RT-PCR. The expression of the gene product (leukocyte surface protein) was examined in 20 chronic HD patients by flow cytometry. Results: In addition to the inflammatory cytokines, the urokinase plasminogen activator receptor (uPAR or CD87) gene was induced in leukocytes treated with each dialysis membrane. The extent of induction depended on the membrane’s material composition. The expression of the uPAR (CD87) protein on leukocytes was markedly increased in patients undergoing dialysis therapy. The magnitude of uPAR (CD87) protein expression was correlated with clinical findings, i.e., the degree of leukopenia and the expression of adhesion molecules. Conclusions: The gene and protein expression of uPAR (CD87) depended on the dialysis membrane material and correlated closely with clinical findings. These results suggest that uPAR has the potential to serve as a marker not only for clinical use but also for the development of new dialysis membranes.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Sagedal S, Hartmann A, Sundstrøm K, Bjørnsen S, Brosstad F: Anticoagulation intensity sufficient for hemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant 2001;16:987–993.
  2. Craddock PR, Fehr J, Brigham KL, Kronenberg RS, Jacob HS: Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med 1977;296:769–774.
  3. Varela MP, Kimmel PL, Philips TM, Mishkin GJ, Lew SQ, Bosch JP: Biocompatibility of hemodialysis membranes: interrelations between plasma complement and cytokine levels. Blood Purif 2001;19:370–379.
  4. Rostaing L, Peres C, Tkaczuk J, Charlet JP, Bories P, Durand D, Ohayon E, Préval C, Abbal M: Ex vivo flow cytometry determination of Intracytoplasmic expression of IL-2, IL-6, IFNIγ and TNF-α in monocytes and T lymphocytes, in chronic hemodialysis patients. Am J Nephrol 2000;20:18–26.
  5. Pascual M, Tolkoff-Rubin N, Schifferli JA: Is adsorption an important characteristic of dialysis membrane? Kidney Int 1996;49:309–313.
  6. Akizawa T, Kino K, Kinugasa E, Koshikawa S, Ikada Y, Kishida A, Hatanaka Y, Imamura K: Clinical effects of a polyethylene glycol grafted cellulose membrane on thrombogenicity and biocompatibility during hemodialysis. ASAIO Trans 1990;36:M640–M642.
  7. Cases A, Reverter JC, Escolar G, Sanz C, Sorribes J, Ordinas A: In vivo evaluation of platelet activation by different cellulosic membranes. Artif Organs 1997;21:330–334.
  8. Sanaka T, Nishikawa M, Suzuki T, Higuchi C, Sato T, Hayasaka Y, Teraoka S, Agishi T, Ota K, Sugino N: Production of reactive oxygen metabolites during hemodialysis – a proposal of reactive oxygen metabolites hypothesis in patients under maintenance hemodialysis. Artif Organs Today 1991;1:129–134.
  9. Tsuruoka S, Kawaguchi A, Nishiki K, Hayasaka T, Fukushima C, Sugimoto K, Saito T, Fujimura A: Vitamin E-bonded hemodialyzer improves neutrophil function and oxidative stress in patients with end-stage renal failure. Am J Kidney Dis 2002;39:127–133.
  10. Wrrko-Sarsat V, Friendlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Decamps-Latscha B: Advanced oxidation protein product as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304–1313.
  11. Qian J, Yu Z, Dai H, Zhang Q, Chen S: Influence of hemodialysis membranes on gene expression and plasma levels of interleukin-1β. Artif Organs 1995;19:842–846.
  12. Pertosa G, Grandaliano G, Gesualdo L, Ranieri E, Monno R, Schena P: Interleukin-6, interleukin-8 and monocyte chemotactic peptide-1 gene expression and protein synthesis are independently modulated by hemodialysis membranes. Kidney Int 1998;54:570–579.
  13. Roccatello D, Menegatti E, Alfieri V, Rossi D, DeLuca A, Pignone E, Mengozzi G, Cesano G, Formica M, Martina G, Sena LM, Piccoli G: Intradialytic cytokine gene expression. Blood Purif 1998;16:30–36.
  14. Qian J, Yu Z, Dai H, Huang P, Zhang Q, Cheng F, Chen S: The study of IL-1β, TNF-α, IL-6 gene expression and plasma levels on hemodialysis before and after dialyzer reuse. Chin Med J (Engl) 1997;110:508–511.
  15. Sirolli V, Di Stante S, Stuard S, Di Liberato L, Amoroso L, Cappelli P, Bonomini M: Biocompatibility and functional performance of a polyethylene glycol acid-grafted cellulosic membrane for hemodialysis. Int J Artf Organs 2000;23:356–364.
  16. Niwa T, Miyazaki T, Sato M, Kambe F, Tsuzuki T, Uema K, Maeda K, Seo H: Interleukin 8 and biocompatibility of dialysis membranes. Am J Nephrol 1995;15:181–185.
  17. Kushihata S, Yorioka N, Oda H, YE XF, Yamakido M: Effects of dialysis membranes on the kinetics of tumor necrosis factor-α production by peripheral mononuclear cells in chronic hemodialysis patients. Int J Artif Organs 1998;21:384–390.
  18. Weber N, Wendel HP, Ziemer G: Gene monitoring of surface-activated monocytes in circulating whole blood using duplex RT-PCR. J Biomed Mater Res 2001;56:1–8.
  19. Stahl A, Mueller BM: The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J Cell Biol 1995;129:335–344.
  20. Gyetko MR, Sitrin RG, Fuller JA, Todd III RF, Petty H, Standiford TJ: Function of the urokinase receptor (CD87) in neutrophil chemotaxis. J Leukocyte Biol 1995;58:533–538.
  21. Simon DI, Rao NK, Xu H, Wei Y, Majdic O, Ronne E, Kobzik L, Chapman HA: Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 1996;88:3185–3194.
  22. Schmitt M, Wilhelm O, Jänicke F, Magdolen V, Reuning U, Ohi H, Moniwa N, Kobayashi H, Weidle U, Graeff H: Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invention and metastasis. J Obstet Gynaecol 1995;21:151–165.
  23. Blasi F: The urokinase receptor. A cell surface, regulated chemokine. APMIS 1999;107:96–101.
  24. Florquin S, Van den Berg JG, Olszyna DP, Claessen N, Opal SM, Weening JJ, Van der Poll T: Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int 2001;59:2054–2061.
  25. Cheung AK, Parker CJ, Wilcox L, Janatova J: Activation of the alternative pathway of complement by cellulosic hemodialysis membranes. Kidney Int 1989;36:257–265.
  26. Lhotta K, Würzner R, Kronenberg F, Oppermann M, König P: Rapid activation of the complement system by cuprophane depends on complement component C4. Kidney Int 1998;53:1044–1051.
  27. Omata M, Higuchi C, Demura R, Sanaka T, Nihei H: Reduction of neutrophil activation by vitamin E modified dialyzer membranes. Nephron 2000;85:221–231.
  28. Dhondt A, Vanholder R, Glorieux G, Waterloos MA, Smet RD, Lesaffer G, Lameire N: Vitamin E-Bonded cellulose membrane and hemodialysis biocompatibility: Absence of acute benefit on expression of leukocyte surface molecules. Am J Kidney Dis 2000;36:1140–1146.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50